JEFFREY M. DAYNO, M.D.

EVP & Chief Medical Officer

 

Jeffrey M. Dayno, M.D. is Executive Vice President and Chief Medical Officer of Harmony Biosciences, an innovative biopharmaceutical company dedicated to identifying, developing and commercializing novel treatment options for patients with rare diseases. Dr. Dayno is a nationally-recognized expert in neuroscience and is currently responsible for managing research, development and medical and regulatory affairs for Harmony Biosciences, which is focused on developing novel treatments for Central Nervous System disorders.

Dr. Dayno has more than 20 years of experience in the pharmaceutical and biotech industry, having started his career at Merck & Co., Inc.  After Merck, he joined Cephalon as the Vice President of Medical Affairs, where he built out a global Medical Affairs organization and also directed the Phase 3B/4 Clinical Development program focused on treatments for sleep disorders.  He went on to become the Chief Medical Officer at Labopharm, Inc. and then, after it was acquired by Paladin Labs, served as Vice President of Global Medical Affairs at ViroPharma, Inc.  At ViroPharma, Dr. Dayno helped to lead early clinical development efforts with a focus on rare neurologic disorders. In addition, Dr. Dayno was Chief Medical Officer at Egalet Corporation, a specialty pharmacy company which develops innovative pain medications, focusing on abuse-deterrent formulation development.

Dr. Dayno earned his medical degree from Temple University School of Medicine, did his residency training in Neurology at Temple University Hospital, and completed a fellowship in Stroke and Cerebrovascular Disorders in the Department of Neurology at Henry Ford Hospital, which was a National Institutes of Health (NIH) Clinical Research Center for Stroke and Headache.  He was board certified in Neurology and spent 10 years in clinical and academic medicine before going into Industry.  He served on the faculty of Jefferson Medical College, where he was an Assistant Professor of Neurology, the Medical Director of the Jefferson Health System Stroke Center Network, and an attending physician in the Jefferson Headache Center.

Dr. Dayno has served as Principal Investigator on numerous clinical trials and published and lectured extensively on various topics in the field of Neurology, with a focus on stroke, sleep disorders, pain and migraine.  He has participated on several FDA/Industry panels regarding drug development and was a member of the STAIR (Stroke Trials Academic Industry Regulatory) Task Force which developed clinical trial guidelines for acute stroke research trials.  Dr. Dayno is a member of the Board of Visitors of the Lewis Katz School of Medicine at Temple University and is on the Board of Directors of Atrin Pharmaceuticals.